3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
NETWORK
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Marijuana Abuse
2
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Pancreatic Cancer Non-resectable
1
Pain
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Marijuana Use
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
Carcinoma, Hepatocellular
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Interventions
Sirolimus
4
LY3295668 erbumine
3
Everolimus
3
Anticonvulsants
2
perampanel
1
clevidipine
1
brivaracetam
1
Vigabatrin
1
Topotecan
1
Therapeutic Touch
1
Temozolomide
1
TAS-119
1
Sulfasalazine
1
Sevoflurane
1
Saline Solution
1
Radiotherapy
1
Propofol
1
Paclitaxel
1
Nitrous Oxide
1
Midazolam
1
Memantine
1
Medical Marijuana
1
Lidocaine
1
Levetiracetam
1
Ketamine
1
Immunoglobulins, Intravenous
1
Glycopyrrolate
1
Gabapentin
1
Fluid Therapy
1
Fentanyl
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Epilepsy
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled